BN Business News
Add your company to Business Communicator →

Business · 22/06/2011Updated: 10/17/2026 · 1 min read

National Institutes of Health Grants Exclusive Patent License for Ulipristal Acetate Treatment of Uterine Fibroids

Summary

The National Institutes of Health is considering granting an exclusive patent license to PregLem SA to practice ulipristal acetate for treating symptomatic uterine fibroids, with the rights assigned to the US government and Laboratoire HRA Pharma.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →